The number of pipeline General Surgery products in 2021 saw a 50% rise globally when compared to General Surgery pipeline products in 2020, according to GlobalData’s pipeline products database. This compares to an 15% rise for all pipeline medical devices in 2021 compared to 2020.
The global General Surgery market was worth $63.16bn in 2020 and is expected to reach $63.76bn by 2025, according to GlobalData’s analysis.
General Surgery pipeline products by categories: Endoscopy Devices has the most devices
Looking at the device categories of pipeline products, Endoscopy Devices accounted for the largest proportion (19.83%) in 2021, followed by Robotic Surgery (13.92%) and Aesthetic Devices (13.5%).
Of the global medical devices market value, the General Surgery market held a 12% share worth $63bn in 2021 and is expected to reach $63.76bn by 2025.
General Surgery development activity: Advanced stage of development leads
Devices at an advanced stage of development (in clinical trials, in the approval process, already approved in Europe or the rest of the world) accounted for 38.91% of medical devices in 2021, compared with 53.29% in 2020. The number of devices at the In Approval stage declined by 26% in 2021, when compared with 2020.
The In Approval stage is considered to be the period where the manufacturer is waiting for final approval from regulators, following completion of the required development steps.
A decrease in products awaiting approval would indicate less new products entering the market in the coming months, while an increase indicates more devices entering the market, posing a market share threat to existing marketed devices.
North America tops pipeline General Surgery products activity
Comparing the number of pipeline General Surgery products activity in different regions of the globe, North America held the top position (45%) during 2021, followed by Asia-Pacific (28%), and Europe (23%).
On a country level, the US had the most pipeline General Surgery during the year, representing the largest share (45%) of General Surgery pipeline products. In second place was China (15%), followed by India (5%).
New pipeline General Surgery medical devices: Expected to be approved by 2025
According to GlobalData, approximately 51% of pipeline General Surgery in 2021 were expected to receive regulatory approval by the end of 2025. The leading categories for devices expected to receive regulatory approval by the end of 2025 was Robotic Surgical Systems, at 6% of devices. Differences in regulatory approval timelines reflect the stage of development for a device, the device complexity or risk categorization (or device class) or if there are changes in regulatory oversight.
Stryker Corp tops General Surgery development in 2021
According to GlobalData, top ten medical device companies accounted for 18.99% of pipeline General Surgery activity during 2021. The leading company for developing General Surgery was Stryker Corp with 2.95%, followed by Boston Scientific Corp at 2.53%.
Companies launching new medical devices are more likely to disrupt existing market share or are better able to defend existing share.
Company-developed pipeline products lead General Surgery in development
Looking at the share of activity in terms of General Surgery pipeline products developers, company-developed pipeline products accounted for an 89% share of the General Surgery medical devices market, while institute-developed pipeline products held the remaining share.
The monthly average for 2021 saw company-developed General Surgery pipeline products account for 89% of pipeline products and institute-developed pipeline products account for 11%.
The medical devices pipeline data used in this article were extracted from Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database covers all medical devices which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Pipeline products are covered from various authenticated sources like company websites, SEC filings, conference presentations, analyst presentations, news releases, grants etc. The information is collected by following systematic research techniques and proprietary methodology.